First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study

被引：0

作者：

Andreis, D.

Scandurra, G.

Santini, D.

Gucciardino, C.

La Verde, N. M.

Girelli, S.

Alabiso, I.

Saetta, A.

Atzori, F.

Collova, E.

Ferzi, A.

Gori, S.

Lipari, H.

Saggia, C.

Marcon, I.

Generali, D. G.

机构：

[1] AO Ist Ospitalieri Cremona, UO Multidisciplinare Patol Mammaria, Cremona, Italy

[2] Day Hop, Humanitas Ctr Catanese Oncol, Catania, Italy

[3] Univ Campus Biomed Roma, Dipartimento Med Oncol, Rome, Italy

[4] AO Fatebenefratelli & Oftalm, UO Oncol Med, Milan, Italy

[5] Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy

[6] Fdn Ist San Raffaele D Giglio di Cefalu, UO Oncol, Cefalu, Italy

[7] AOU Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy

[8] Osped Civile Legnano, Legnano, Italy

[9] AO Perugia, Oncol Med, Perugia, Italy

[10] Cannizzaro Hosp, Div Med Oncol, Catania, Italy

[11] AOU Osped Maggiore della Carita, SCDU Oncol, Novara, Italy

[12] AO Osped Circolo, UO Oncol, Varese, Italy

[13] Fdn Macchi, Varese, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.e11502

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e11502

引用

页数：1

共 50 条

[21] Bevacizumab A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer [J].

Croom, Katherine F. ;

Dhillon, Sohita .

DRUGS, 2011, 71 (16) :2213-2229

[22] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients [J].

Fabi, A. ;

Russillo, M. ;

Metro, G. ;

Papaldo, P. ;

Nistico, C. ;

Ferretti, G. ;

Cuppone, F. ;

D'Auria, G. ;

Giannarelli, D. ;

Cognetti, F. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[23] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer [J].

Babacan, Taner ;

Efe, Orhan ;

Hasirci, Ahmet S. ;

Demirci, Fatih ;

Buyukhatipoglu, Hakan ;

Balakan, Ozan ;

Sarici, Furkan ;

Kertmen, Neyran ;

Esin, Ece ;

Akin, Serkan ;

Ates, Ozturk ;

Aksoy, Sercan ;

Sever, Ali R. ;

Altundag, Kadri .

TUMORI JOURNAL, 2015, 101 (04) :418-423

[24] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION [J].

Kourea, H. P. ;

Koutras, A. K. ;

Kotoula, V. ;

Bobos, M. ;

Fountzila, A. Kalogera ;

Papazisis, K. T. ;

Christodoulou, C. ;

Res, E. ;

Bournakis, E. ;

Fountzilas, G. .

ANNALS OF ONCOLOGY, 2010, 21 :104-104

[25] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer [J].

Tryfonidis, K. ;

Boukovinas, I. ;

Xenidis, N. ;

Christophyllakis, C. ;

Papakotoulas, P. ;

Politaki, E. ;

Malamos, N. ;

Polyzos, A. ;

Kakolyris, S. ;

Georgoulias, V. ;

Mavroudis, D. .

BREAST, 2013, 22 (06) :1171-1177

[26] Primary endpoints in first-line trials in patients with HER2-negative/-unknown metastatic breast cancer (MBC) [J].

Kuemmel, S. ;

Mueller, V ;

Lux, M. P. ;

Weyer, G. ;

Pintoffl, J. P. ;

Jackisch, C. .

ONKOLOGIE, 2012, 35 :66-+

[27] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study [J].

Hardy-Bessard, Anne-Claire ;

Brocard, Fabien ;

Clatot, Florian ;

Lortholary, Alain ;

You, Benoit ;

Grenier, Julien ;

Martin-Babau, Jerome ;

Lucas, Brigitte ;

Meunier, Jerome ;

Ferrero, Jean-Marc ;

Savoye, Aude-Marie ;

Marti, Adina ;

Despax, Raymond ;

Moullet, Isabelle ;

Emile, George .

BREAST, 2020, 54 :256-263

[28] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer [J].

Esteva, F. J. ;

Franco, S. X. ;

Hagan, M. K. ;

Somer, R. A. ;

Dombroski, C. S. ;

Florance, A. M. ;

Turner, S. J. ;

Stein, S. ;

Perez, A. .

CANCER RESEARCH, 2009, 69 (24) :793S-793S

[29] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy [J].

Alessandra Fabi ;

Michelangelo Russillo ;

Gianluigi Ferretti ;

Giulio Metro ;

Cecilia Nisticò ;

Paola Papaldo ;

Ferdinando De Vita ;

Giuliana D’Auria ;

Antonello Vidiri ;

Diana Giannarelli ;

Francesco Cognetti .

BMC Cancer, 12

[30] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy [J].

Fabi, Alessandra ;

Russillo, Michelangelo ;

Ferretti, Gianluigi ;

Metro, Giulio ;

Nistico, Cecilia ;

Papaldo, Paola ;

De Vita, Ferdinando ;

D'Auria, Giuliana ;

Vidiri, Antonello ;

Giannarelli, Diana ;

Cognetti, Francesco .

BMC CANCER, 2012, 12

← 1 2 3 4 5 →